S&P 500   3,002.66 (+1.23%)
DOW   27,087.44 (+1.12%)
QQQ   193.95 (+1.50%)
AAPL   235.81 (-0.03%)
FB   189.69 (+3.50%)
MSFT   141.57 (+1.45%)
GOOGL   1,245.75 (+2.30%)
AMZN   1,774.87 (+2.21%)
NVDA   197.72 (+6.00%)
MU   46.47 (+3.59%)
BABA   175.42 (+2.49%)
TSLA   259.00 (+0.79%)
AMD   30.89 (+1.18%)
F   9.08 (+2.83%)
ACB   3.81 (+8.56%)
BAC   29.99 (+2.92%)
GILD   65.55 (+1.61%)
DIS   130.26 (+0.43%)
S&P 500   3,002.66 (+1.23%)
DOW   27,087.44 (+1.12%)
QQQ   193.95 (+1.50%)
AAPL   235.81 (-0.03%)
FB   189.69 (+3.50%)
MSFT   141.57 (+1.45%)
GOOGL   1,245.75 (+2.30%)
AMZN   1,774.87 (+2.21%)
NVDA   197.72 (+6.00%)
MU   46.47 (+3.59%)
BABA   175.42 (+2.49%)
TSLA   259.00 (+0.79%)
AMD   30.89 (+1.18%)
F   9.08 (+2.83%)
ACB   3.81 (+8.56%)
BAC   29.99 (+2.92%)
GILD   65.55 (+1.61%)
DIS   130.26 (+0.43%)
Log in

TESARO Stock Price, News & Analysis (NASDAQ:TSRO)

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
VolumeN/A
Average Volume1.97 million shs
Market Capitalization$4.13 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.38
Tesaro, Inc, an oncology-focused biopharmaceutical company, identifies, acquires, develops, and commercializes cancer therapeutics and oncology supportive care products in the United States. It offers ZEJULA (niraparib), an orally active and potent poly polymerase inhibitor for the maintenance treatment of women with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer; and VARUBI (rolapitant), a neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:TSRO
CUSIP88156910
Phone339-970-0900

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$223.33 million
Book Value$4.58 per share

Profitability

Net Income$-496,120,000.00
Net Margins-295.67%

Miscellaneous

EmployeesN/A
Market Cap$4.13 billion
Next Earnings DateN/A
OptionableOptionable

Receive TSRO News and Ratings via Email

Sign-up to receive the latest news and ratings for TSRO and its competitors with MarketBeat's FREE daily newsletter.


TESARO (NASDAQ:TSRO) Frequently Asked Questions

What is TESARO's stock symbol?

TESARO trades on the NASDAQ under the ticker symbol "TSRO."

How were TESARO's earnings last quarter?

TESARO Inc (NASDAQ:TSRO) issued its earnings results on Thursday, August, 2nd. The biopharmaceutical company reported ($3.04) EPS for the quarter, missing analysts' consensus estimates of ($2.66) by $0.38. The biopharmaceutical company earned $57.21 million during the quarter, compared to analysts' expectations of $65.50 million. TESARO had a negative return on equity of 1,209.72% and a negative net margin of 295.67%. The firm's quarterly revenue was up 94.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($2.82) EPS. View TESARO's Earnings History.

What price target have analysts set for TSRO?

16 equities research analysts have issued twelve-month price objectives for TESARO's stock. Their forecasts range from $25.00 to $83.00. On average, they expect TESARO's stock price to reach $65.15 in the next twelve months. View Analyst Price Targets for TESARO.

What is the consensus analysts' recommendation for TESARO?

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TESARO in the last year. There are currently 14 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for TESARO.

What are Wall Street analysts saying about TESARO stock?

Here are some recent quotes from research analysts about TESARO stock:
  • 1. Cantor Fitzgerald analysts commented, ": 12-month PT of $68 on shares of TSRO. Bloomberg reported last week that Tesaro was exploring a sale. We think that the company remains undervalued based on 1) PARP inhibitor potential in first-line ovarian cancer and 2) potential with its immuno-oncology platform (licensed from AnaptysBio, ANAB, OW, covered by Eliana Merle) that is beginning to shape up with data readouts. We also believe that it can take time for deals to emerge, so we think that this press article could be a way of garnering interest for the company beyond potentially initial interest. In the past, we think that this company had been a potential takeout interest from biopharmaceutical companies." (11/19/2018)
  • 2. According to Zacks Investment Research, "TESARO's drug, Zejula has performed well since its approval in early 2017, gaining lead in U.S. ovarian cancer market share in the PARP inhibitor segment. The drug also has bright prospects, given the tremendous demand for PARP inhibitors. Moreover, collaborations with several large pharma companies for the development of Zejula generates a cash flow stream for TESARO and enables sharing of R&D costs. TESARO’s efforts for label expansion of Zejula are also encouraging. However, TESARO is heavily dependent on Zejula for growth, which concerns us. Meanwhile, competition in the PARP inhibitor segment is rising with two other approved drugs and several companies developing their candidates. TESARO’s shares have underperformed the industry so far this year. Loss estimates have widened ahead of the company’s Q3 earnings release. The company has a mixed record of earnings surprises in recent quarters." (10/23/2018)

Has TESARO been receiving favorable news coverage?

News stories about TSRO stock have been trending neutral on Tuesday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. TESARO earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for TESARO.

Who are some of TESARO's key competitors?

What other stocks do shareholders of TESARO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TESARO investors own include NVIDIA (NVDA), Alibaba Group (BABA), Clovis Oncology (CLVS), Netflix (NFLX), Micron Technology (MU), Exelixis (EXEL), Celgene (CELG), Tesla (TSLA), salesforce.com (CRM) and Intel (INTC).

Who are TESARO's key executives?

TESARO's management team includes the folowing people:
  • Mr. Leon O. Moulder Jr., Co-Founder, CEO & Director (Age 62)
  • Dr. Mary Lynne Hedley Ph.D., Co-Founder, Pres, COO & Director (Age 56)
  • Mr. Timothy R. Pearson, Exec. VP & CFO (Age 51)
  • Dr. Martin H. Huber Jr., Sr. VP & Chief Medical Officer (Age 59)
  • Mr. Orlando Oliveira, Sr. VP & GM of International (Age 43)

How big of a company is TESARO?

TESARO has a market capitalization of $0.00 and generates $223.33 million in revenue each year. The biopharmaceutical company earns $-496,120,000.00 in net income (profit) each year or ($9.17) on an earnings per share basis. View Additional Information About TESARO.

What is TESARO's official website?

The official website for TESARO is http://www.tesarobio.com/.

How can I contact TESARO?

TESARO's mailing address is 1000 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 339-970-0900.


MarketBeat Community Rating for TESARO (NASDAQ TSRO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  635 (Thanks for Voting!)
Underperform Votes:  488 (Thanks for Voting!)
Total Votes:  1,123
MarketBeat's community ratings are surveys of what our community members think about TESARO and other stocks. Vote "Outperform" if you believe TSRO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TSRO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel